.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA05_Oritavancin.Oritavancin .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01X_OtherAntibacterials.J01XA05_Oritavancin.Oritavancin| name: | Oritavancin |
| ATC code: | J01XA05 | route: | intravenous |
| n-compartments | 3 |
Oritavancin is a semisynthetic lipoglycopeptide antibiotic used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for use in adults and is administered as a single intravenous dose.
Population pharmacokinetics in healthy adult subjects receiving a single intravenous dose.
Rubino, CM, et al., & Forrest, A (2009). Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrobial agents and chemotherapy 53(10) 4422–4428. DOI:10.1128/AAC.00231-09 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19635952
Dunbar, LM, et al., & Wasilewski, MM (2011). Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrobial agents and chemotherapy 55(7) 3476–3484. DOI:10.1128/AAC.00029-11 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21537018